Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot-Guided brain zaps: a new hope for postpartum depression?

NCT ID NCT07757815

Disease control Sponsor: University of Macau Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study explores whether robot-guided repetitive transcranial magnetic stimulation (rTMS) can effectively treat postpartum depression (PPD). Researchers will compare brain activity, heart signals, blood markers, and body awareness in women with PPD versus healthy controls. Participants with PPD will receive 20 sessions of high-precision rTMS over 4 weeks, and the study will track whether certain biological markers can predict who responds best to treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Repetitive transcranial magnetic stimulation (rTMS) delivered with robot-guided precision
What this could lead to
If successful, this could lead to a more personalized, effective treatment for postpartum depression, using brain and body signals to guide therapy.
What could go wrong
This is an early-stage study, and the treatment may not work for everyone. rTMS can cause side effects like headache or scalp discomfort, and the biomarkers may not reliably predict response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 290 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biological female, aged 18-45 years. * For HR-PPD and LR-PPD groups: Pregnant women in the third trimester (≥ 32 weeks gestation) with a singleton pregnancy. * For HR-PPD group: Beck Depression Inventory (BDI) score ≥ 14 during the third trimester. * For LR-PPD group: BDI score \< 14 during the third trimester, with no history of depression. * For HC group: Healthy women with no pregnancy in the past 12 months. * No history of central nervous system diseases or major medical/surgical conditions. * No history of medication use that may interfere with EEG or ECG measurements. * Willing and able to complete baseline and follow-up assessments and provide written informed consent. Exclusion Criteria: * Multiple pregnancies, preterm labor, or severe pregnancy complications (e.g., pre-eclampsia, gestational diabetes with complications). * Life-threatening emergencies during delivery (e.g., amniotic fluid embolism, major hemorrhage). * Cognitive impairment or language barriers that hinder cooperation with assessments. * History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder). * Other conditions that, in the opinion of the investigator, make the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression, postpartum are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression, postpartum

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kiang Wu Hospital

    Macao, 999078, Macau

  • the Center for Cognitive and Brain Sciences, Research Building N21

    Macao, 999078, Macau

More trials for these conditions

Other studies related to the condition(s) this trial covers.